Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A Phase I, open-label, multicenter, dose escalation study of oral BGJ398, a pan FGFR kinase inhibitor, in adult patients with advanced solid malignancies

 


A Phase I, open-label, multicenter, dose escalation study of oral BGJ398, a pan FGFR kinase inhibitor, in adult patients with advanced solid malignancies


Trial Focus

All Cancers

Objective

         Clinical trial of investigational drug BGJ398 given by mouth.

IRB Protocol #

09-1156

Trial Status

Archived

Principle Investigator

ROSS CAMIDGE

Sponsor

Novartis

Contact

SARAH RIPPKE at (720)848-0685 or RIPPKE.SARAH@UCDENVER.EDU

Location

Clinical Translational Research Center (CTRC) University of Colorado Hospital Clinical Translational Research Center (CTRC) University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last as long as you are responding well to the study drug. A follow up period will consist of a clinic visit after you stop taking the study drug (to follow for any lasting side effects). // Eligibility criteria include but are not limited to 18 years or older with advanced solid tumor(s). Eligibility criteria include but are not limited to 18 years or older with advanced solid tumor(s).